.jpg "uniQure NV (NASDAQ: QURE)")
In a report released yesterday, Madhu Kumar from B.Riley FBR reiterated a Buy rating on uniQure NV (NASDAQ: QURE), with a price target of $50. The company’s shares opened today at $38.84, close to its 52-week high of $40.99.
Kumar commented:
“This morning (August 23), uniQure (QURE) announced the dosing of the first patient in the Phase IIb study of its lead asset, Factor IX (FIX) adeno-associated virus gene therapy (AAV the treatment of hemophilia B. We consider this a positive event for the company, as the dosing of three patients in the Phase IIb would potentially support interim data by YE18, the key potential positive catalyst for QURE shares. We thus reiterate our QURE Buy rating and $50 price target.”
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 28.1% and a 55.0% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Deciphera Pharmaceuticals Inc.
uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $50, which is a 28.7% upside from current levels. In a report issued on August 8, Janney Montgomery also maintained a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $40.99 and a one-year low of $7.52. Currently, uniQure NV has an average volume of 335.4K.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.
